acetoacetic acid 3-(4,4-diphenylpiperidin-1-yl)propyl ester | 116395-62-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: acetoacetic acid 3-(4,4-diphenylpiperidin-1-yl)propyl ester
• 英文别名: 3-(4,4-diphenylpiperid-1-yl)propyl acetoacetate；3-(4,4-Diphenylpiperid-1-yl)-propyl acetoacetate；3-(4,4-diphenylpiperidin-1-yl)propyl 3-oxobutanoate
• CAS: 116395-62-1
• 化学式: C₂₄H₂₉NO₃
• 分子量: 379.499
• InChiKey: UUMOCTWCPZIZME-UHFFFAOYSA-N

物化性质

• 沸点：
  513.3±50.0 °C(Predicted)
• 密度：
  1.099±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  acetoacetic acid 3-(4,4-diphenylpiperidin-1-yl)propyl ester 在 氨 作用下， 以 异丙醇 为溶剂， 生成 4-(4,4-diphenylpiperid-1-yl)-butanol
  参考文献：
  名称：

  Diaryl piperidine containing esters of 1,4-dihydropyridines and coronary

  摘要：

  化学式I的二芳基化合物 其中Ar代表式的环 Y代表氧（O），硫（S），乙烯基（-CH.dbd.CH-），偶氮甲基（-CH.dbd.N-）或式的基团 R1、R2和R3相同或不同，表示氢，C.sub.1-C.sub.6-烷基，C.sub.3-C.sub.7-烷氧基烷基，芳基，芳基-C.sub.1-C.sub.6-烷基或芳氧基-C.sub.1-C.sub.6-烷基，R4和R5相同或不同，表示氢，羟基，卤素，硝基，氰基，三氟甲基，C.sub.1-C.sub.4-烷基，C.sub.1-C.sub.4-烷氧基，完全或部分被氟取代的C.sub.1-C.sub.4-烷氧基羰基，C.sub.2-C.sub.5-酰基，氨基或单或双C.sub.1-C.sub.4-烷基氨基，R6、R7、R8和R9相同或不同，表示氢，羟基，卤素，C.sub.1-C.sub.4-烷基，C.sub.1-C.sub.4-烷氧基，氨基，单或双C.sub.1-C.sub.4-烷基氨基，或完全或部分被氟取代的C.sub.1-C.sub.4-烷氧基，A表示直链或支链C.sub.2-C.sub.5-烷基，可以被C.sub.1-C.sub.4-烷氧基或芳基取代，它们的盐是治疗和预防循环性疾病的新化合物。

  公开号：

  US04707486A1
• 作为产物：
  描述：

  1-(3-hydroxypropyl)-4,4-diphenylpiperidine 以 丙酮 、 甲苯 为溶剂， 生成 acetoacetic acid 3-(4,4-diphenylpiperidin-1-yl)propyl ester
  参考文献：
  名称：

  Diaryl piperidine containing esters of 1,4-dihydropyridines and coronary

  摘要：

  化学式I的二芳基化合物 其中Ar代表式的环 Y代表氧（O），硫（S），乙烯基（-CH.dbd.CH-），偶氮甲基（-CH.dbd.N-）或式的基团 R1、R2和R3相同或不同，表示氢，C.sub.1-C.sub.6-烷基，C.sub.3-C.sub.7-烷氧基烷基，芳基，芳基-C.sub.1-C.sub.6-烷基或芳氧基-C.sub.1-C.sub.6-烷基，R4和R5相同或不同，表示氢，羟基，卤素，硝基，氰基，三氟甲基，C.sub.1-C.sub.4-烷基，C.sub.1-C.sub.4-烷氧基，完全或部分被氟取代的C.sub.1-C.sub.4-烷氧基羰基，C.sub.2-C.sub.5-酰基，氨基或单或双C.sub.1-C.sub.4-烷基氨基，R6、R7、R8和R9相同或不同，表示氢，羟基，卤素，C.sub.1-C.sub.4-烷基，C.sub.1-C.sub.4-烷氧基，氨基，单或双C.sub.1-C.sub.4-烷基氨基，或完全或部分被氟取代的C.sub.1-C.sub.4-烷氧基，A表示直链或支链C.sub.2-C.sub.5-烷基，可以被C.sub.1-C.sub.4-烷氧基或芳基取代，它们的盐是治疗和预防循环性疾病的新化合物。

  公开号：

  US04707486A1

文献信息

• Aromatic amine derivatives
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05508306A1

  公开（公告）日：1996-04-16

  This invention relates to novel aromatic amine compounds having the structure: ##STR1## where each W, Z.sup.1 and Z.sup.2 is independently H, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, OH, F, Cl, Br, I, NO.sub.2, CN, SO.sub.2 NHR.sup.3, NR.sup.4.sub.2, CONR.sup.3.sub.2, COR.sup.5 ; where each R.sup.1 and R.sup.2 is independently H, C.sub.1 -C.sub.6 straight or branched chain alkyl or phenyl; where each X and Y is independently CH.sub.2, NR.sup.4, S, S.dbd.O, SO.sub.2 ; where n is 0, 1 or 2; where each p and q is independently 1 or 2; where R.sup.3 is H, C.sub.1 -C.sub.6 straight or branched chain alkyl or phenyl; where R.sup.4 is H, C.sub.1 -C.sub.6 straight or branched chain alkyl or COR.sup.3 ; and where R.sup.5 is H, C.sub.1 -C.sub.6 straight or branched chain alkyl or phenyl, C.sub.1 -C.sub.6 straight or branched chain alkoxy or OH. In addition the invention includes using such compounds for the treatment of benign prostatic hyperplasia, lowering intraocular pressure and inhibiting cholesterol synthesis.

  这项发明涉及具有以下结构的新型芳香胺化合物：其中每个W，Z.sup.1和Z.sup.2独立地为H，C.sub.1 -C.sub.6烷基，C.sub.1 -C.sub.6烷氧基，OH，F，Cl，Br，I，NO.sub.2，CN，SO.sub.2NHR.sup.3，NR.sup.4.sub.2，CONR.sup.3.sub.2，COR.sup.5；其中每个R.sup.1和R.sup.2独立地为H，C.sub.1 -C.sub.6直链或支链烷基或苯基；其中每个X和Y独立地为CH.sub.2，NR.sup.4，S，S.dbd.O，SO.sub.2；其中n为0、1或2；其中每个p和q独立地为1或2；其中R.sup.3为H，C.sub.1 -C.sub.6直链或支链烷基或苯基；其中R.sup.4为H，C.sub.1 -C.sub.6直链或支链烷基或COR.sup.3；其中R.sup.5为H，C.sub.1 -C.sub.6直链或支链烷基或苯基，C.sub.1 -C.sub.6直链或支链烷氧基或OH。此外，该发明还包括使用这些化合物治疗良性前列腺增生、降低眼内压和抑制胆固醇合成。
• Use of .alpha.-1C specific compounds to treat benign prostatic
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05578611A1

  公开（公告）日：1996-11-26

  The subject invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, a human histamine H.sub.1 receptor and .alpha..sub.2 adrenergic receptor. The subject invention also provides a method of inhibiting contraction of prostate tissue which comprises contacting the prostate tissue with an effective contraction-inhibiting amount of such compound.

  该发明提供了一种治疗良性前列腺增生的方法，包括向受试者施用一种与人类α1C肾上腺素受体结合的化合物的治疗有效量，其结合亲和力比化合物与人类α1A肾上腺素受体、人类α1B肾上腺素受体、人类组胺H1受体和α2肾上腺素受体结合的亲和力高出十倍以上。该发明还提供了一种抑制前列腺组织收缩的方法，包括用该化合物接触前列腺组织，使其受到有效的抑制收缩作用的量。
• Use of .alpha..sub.1C specific compounds to treat benign prostatic
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05403847A1

  公开（公告）日：1995-04-04

  A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor, and, binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such .alpha..sub.1C adrenergic receptor. Compounds meeting these criteria are provided.

  一种治疗良性前列腺增生的方法，包括向患者投与一种与人类α1C肾上腺素受体结合的化合物的治疗有效量，其结合亲和力比其与人类α1A肾上腺素受体、人类α1B肾上腺素受体和人类组胺H1受体结合的亲和力高出十倍以上，并且与人类α2肾上腺素受体结合的亲和力比其与该α1C肾上腺素受体结合的亲和力低出十倍以上。提供符合这些标准的化合物。
• .alpha..sub.1C specific compounds to treat benign prostatic hyperplasia
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US05990128A1

  公开（公告）日：1999-11-23

  This invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of an .alpha..sub.1C antagonist which (a) binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than 100-fold higher than the binding affinity with which the .alpha..sub.1C antagonist binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor; and (b) binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than 100-fold lower than the binding affinity with which the .alpha..sub.1C antagonist binds to such .alpha..sub.1C adrenergic receptor. The invention further provides a method of inhibiting contraction of a prostate tissue which comprises contacting the prostate tissue with an effective contraction-inhibiting amount of an .alpha..sub.1C antagonist which (a) binds to a human .alpha..sub.1C adrenergic receptor with a binding affinity greater than 100-fold higher than the binding affinity with which the .alpha..sub.1C antagonist binds to a human .alpha..sub.1A adrenergic receptor, a human .alpha..sub.1B adrenergic receptor, and a human histamine H.sub.1 receptor; and (b) binds to a human .alpha..sub.2 adrenergic receptor with a binding affinity which is greater than 100-fold lower than the binding affinity with which the .alpha..sub.1C antagonist binds to such .alpha..sub.1C adrenergic receptor.

  该发明提供了一种治疗良性前列腺增生的方法，该方法包括向受试者施用治疗有效量的α1C受体拮抗剂，该拮抗剂（a）与人类α1C肾上腺素受体结合的亲和力比其与人类α1A肾上腺素受体、人类α1B肾上腺素受体和人类组织胺H1受体结合的亲和力高100倍以上；以及（b）与人类α2肾上腺素受体结合的亲和力比其与该α1C肾上腺素受体结合的亲和力低100倍以上。该发明还提供了一种抑制前列腺组织收缩的方法，该方法包括将前列腺组织与有效的抑制收缩量的α1C受体拮抗剂接触，该拮抗剂（a）与人类α1C肾上腺素受体结合的亲和力比其与人类α1A肾上腺素受体、人类α1B肾上腺素受体和人类组织胺H1受体结合的亲和力高100倍以上；以及（b）与人类α2肾上腺素受体结合的亲和力比其与该α1C肾上腺素受体结合的亲和力低100倍以上。
• Optically-active 1,4-dihydropyridine
  申请人：Byk Gulden Lomberg Chemische Fabrik GmbH

  公开号：US04975440A1

  公开（公告）日：1990-12-04

  The invention relates to 3-methyl-5-[3-(4,4-diphenylpiperid-1-yl)-propyl] (+)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-piperidine-3,5-dicarboxylat e and its salts and to their preparation and use.

  该发明涉及3-甲基-5-[3-(4,4-二苯基哌啶-1-基)-丙基](+)-1,4-二氢-2,6-二甲基-4-(3-硝基苯基)-哌啶-3,5-二羧酸盐及其盐的制备和用途。